Dermato-Onco2024 | Tissue-based profiling to predict SLN positivity in high-risk melanoma
Julian Kӧtt
• 5 Nov 2024
Julian Kӧtt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses the prognostic value of tissue-based profiling to detect sentinel lymph node (SLN) positivity in patients with high-risk melanoma. Gene expression profiling (GEP) has shown that it can precede sentinel lymph node (SLN) biopsies and improve the prognosis for melanoma-specific survival rates. SLN tissue-based profiling could lead to the initiation of early adjuvant therapies in patients with high-risk melanoma. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
